Pura Vida Investments’s Moderna MRNA Stock Holding History

Pura Vida Investments’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-26,791	Closed	-$3.51M	–	261
2021 Q1	$3.51M	Buy	+26,791	New	+$3.88M	0.1%	135

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pura Vida Investments's MRNA Position: Q2 2021 in Review

Pura Vida Investments sold out of Moderna (MRNA) in Q2 2021, closing a stake of 26,791 shares — an estimated $3.51M sold.

Pura Vida Investments first reported a position in MRNA in Q1 2021 and held it in 1 quarter. The position peaked at $3.51M in Q1 2021. 904 funds tracked by Wall St. Rank hold MRNA as of Q2 2021.

Pura Vida Investments reported no remaining Moderna position as of Q2 2021 after selling out during the quarter.
Pura Vida Investments sold 26,791 Moderna shares in Q2 2021, an estimated $3.51M.
Pura Vida Investments first reported a position in Moderna in Q1 2021 and held it in 1 quarter.
Pura Vida Investments's Moderna position peaked at $3.51M in Q1 2021.
904 funds tracked by Wall St. Rank held Moderna as of Q2 2021.

Based on Pura Vida Investments's 13F filing for Q2 2021, filed 16 Aug 2021.